We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Brain-derived Neurotrophic Factor Participates in Visceral Hyperalgesia in Irritable Bowel Syndrome (IBS) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00925223
Recruitment Status : Unknown
Verified October 2009 by Shandong University.
Recruitment status was:  Enrolling by invitation
First Posted : June 22, 2009
Last Update Posted : October 14, 2009
Information provided by:

Study Description
Brief Summary:
Brain-derived neurotrophic factor (BDNF), originally known to be a member of the nerve growth factor family, has aroused attention as a modulator in visceral hyperalgesia recently. Visceral hypersensitivity is recognized as a clinical hallmark in IBS patients. So in this study, the investigators will focus on the role of BDNF in colonic hyperalgesia in IBS patients.

Condition or disease
Irritable Bowel Syndrome

Study Design

Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Case Control
Official Title: Study of Brain-derived Neurotrophic Factor in Visceral Hyperalgesia in IBS Patients
Study Start Date : June 2009
Estimated Primary Completion Date : August 2009
Estimated Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

irritable bowel syndrome
patients with diarrhea-predominant IBS will be enrolled in this group.
control group
patients with colon cancer or colon polyp will be enrolled as control group.

Outcome Measures

Biospecimen Retention:   Samples With DNA
two mucosal biospecimens will be obtained from the rectosigmoid junction from each patient.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain or discomfort associated with altered bowel habits in the absence of structural and biochemical abnormalities.

Inclusion Criteria:

  • Patients diagnosed with irritable bowel syndrome.

Exclusion Criteria:

  • Patients have similar clinical symptoms as IBS, yet there is morphologic changes in the intestine.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00925223

Sponsors and Collaborators
Shandong University
Study Director: Yanqing Li, PhD. MD. Department of Gastroenterology, Qilu Hospital, Shandong University
More Information

Responsible Party: Yanqing Li, Qilu hospital of Shandong University
ClinicalTrials.gov Identifier: NCT00925223     History of Changes
Other Study ID Numbers: 2009SDU-QILU-G02
First Posted: June 22, 2009    Key Record Dates
Last Update Posted: October 14, 2009
Last Verified: October 2009

Keywords provided by Shandong University:
visceral hypersensitivity

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Pathologic Processes
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms